Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Acute Kidney Injury | Current Treatment | US | 2018

Login to access report north_east
Contact sales account_box

Acute kidney injury (AKI) is defined as functional or structural abnormalities of the kidneys that cause sudden impairment of fluid homeostasis, resulting in retention of metabolic products over a period of hours to days. Diagnosis of AKI is challenging. Sometimes the symptoms are not evident, and they can be fatal by the time they are noticeable. The disease is increasingly common and potentially a catastrophic complication in hospitalized patients. This content examines the management of AKI from the perspective of nephrologists and critical care physicians. It provides a detailed and expanded analysis on the causes of AKI, the utility of current diagnosis methods, AKI staging criteria, and the treatment of AKI (such as fluid management, continuous veno-venous hemofiltration, intermittent hemodialysis, N-acetylcysteine, prednisone, and sodium bicarbonate). In addition, it discusses how nephrologists and critical care physicians perceive future treatment of AKI.

QUESTIONS ANSWERED

  • What are the common underlying causes of AKI?
  • What are the comorbidities and risk factors associated with AKI?
  • What percentage of patients present with AKI versus develop it in the hospital?
  • What are the roles and utility of biomarkers in diagnosing AKI and assessing the efficacy of treatment?
  • What are the main challenges faced in the management of AKI?
  • How frequently do physicians use RIFLE, AKIN, and KDIGO guidelines for AKI?

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.

GEOGRAPHIES

United States

PRIMARY RESEARCH

Survey of 64 nephrologists and 36 critical care physicians in the United States.

KEY TREATMENTS COVERED

Intermittent hemodialysis, continuous veno-venous hemofiltration, fluid management, sodium bicarbonate, N-acetylcysteine, prednisone

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Asthma – Unmet Need – Unmet Need – Severe Asthma (US/EU)
Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer…
north_east
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
north_east
Report
Asthma – Access & Reimbursement – Access & Reimbursement – Asthma (US)
The dynamics within the LABA/ICS FDC, LAMA, LABA/LAMA/ICS FDC, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GSK’s…
north_east
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
north_east
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east